Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Prestained Protein Marker (Triple color, EDTA free, 10-250 k
2026-07-14
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides clear, color-distinct molecular weight standards for SDS-PAGE and Western blot analysis, reducing ambiguity in band identification and transfer efficiency checks. It is ideal for workflows requiring compatibility with Phosbind SDS-PAGE or fluorescent membrane imaging, but should not be used in protocols demanding EDTA or involving protease-sensitive applications outside its validated range.
Sex-Specific Mechanisms in Angiotensin II-Induced Hypertensi
2026-07-14
Xue et al. provide the first detailed analysis of sex differences in angiotensin II-induced hypertension in conscious mice, revealing that male mice develop more pronounced hypertension and altered baroreflex control compared to females. These findings highlight the crucial role of sex hormones in cardiovascular modeling and have practical implications for future hypertension research protocols.
ERK5 and MEK1/2 Pathway Roles in Vitamin D3-Induced AML Diff
2026-07-13
This study delineates the distinct contributions of ERK5 and MEK1/2 signaling in 1α,25-dihydroxyvitamin D3-induced terminal differentiation of acute myeloid leukemia (AML) cells. The findings suggest that targeting these pathways differentially modulates myeloid marker expression and cell cycle dynamics, providing mechanistic insight for combination strategies in leukemia research.
U0126: Precision MEK1/2 Inhibitor Empowering Neurobiology Re
2026-07-13
U0126, a potent MEK1/2 inhibitor from APExBIO, drives high-fidelity MAPK/ERK pathway dissection in neurodegeneration and cancer studies. Its selective, non-ATP-competitive profile enables advanced experimental workflows and robust troubleshooting, ensuring reproducible, mechanistic insights. Explore how recent breakthroughs translate to actionable protocols and optimized outcomes.
ERK5 and ERK1/2 Pathways in Vitamin D3-Induced AML Different
2026-07-12
This study elucidates distinct roles for ERK5 and ERK1/2 MAPK pathways in the terminal differentiation of acute myeloid leukemia (AML) cells induced by 1α,25-(OH)2 vitamin D3. The findings highlight that ERK5 inhibition enhances general myeloid differentiation markers but suppresses monocytic markers, while ERK1/2 inhibition broadly impairs differentiation, offering new mechanistic insights relevant for therapeutic strategy design.
Angiotensin 1/2 (1-6): Precision in Renin-Angiotensin System
2026-07-10
Angiotensin 1/2 (1-6) empowers cardiovascular, renal, and viral pathogenesis research with its high-purity Asp-Arg-Val-Tyr-Ile-His sequence and robust solubility profile. Explore workflow enhancements, troubleshooting strategies, and practical insights that set this APExBIO peptide apart for advanced mechanistic studies.
Applied Workflows with Ganetespib (STA-9090) in Cancer Resea
2026-07-09
Ganetespib (STA-9090) enables precise Hsp90 chaperone disruption for robust tumor growth inhibition in diverse preclinical cancer models. This article distills actionable protocols, troubleshooting guidance, and critical cross-domain insights to maximize experimental reproducibility and translational impact.
KLF4 Directs Isoform-Specific Transcription of AgRP in Mice
2026-07-09
This study uncovers how Krüppel-like factor 4 (KLF4) regulates the expression of three unique isoforms of Agouti-related peptide (AgRP) in mice, highlighting cell-type specificity and context-dependent mechanisms in energy balance and obesity. The findings offer new insight into transcriptional plasticity and the interplay between MAPK/ERK signaling and metabolic regulation.
RSL3 and the Future of Ferroptosis: From Mechanism to Transl
2026-07-08
Explore the mechanistic underpinnings and translational opportunities of (1S,3R)-RSL3, a potent glutathione peroxidase 4 inhibitor, as a cutting-edge ferroptosis inducer in cancer research. This article integrates the latest insights on redox biology, oncogenic RAS synthetic lethality, and actionable best practices for leveraging RSL3 in preclinical workflows—while critically appraising how the miR-18a/ALOXE3 axis, as described in recent glioblastoma research, reframes our understanding of therapeutic vulnerabilities.
α-Bungarotoxin: Mechanistic Insights and Translational Impac
2026-07-08
Explore the mechanistic depth of α-Bungarotoxin in selective nicotinic receptor blockade, with a focus on advanced cholinergic neurotransmission inhibition and translational implications for neurotoxicity and placental necroptosis models. Uncover unique scientific perspectives and practical assay guidance beyond standard protocols.
Lanabecestat (AZD3293): Precision BACE1 Inhibition in Alzhei
2026-07-07
Lanabecestat (AZD3293) empowers Alzheimer’s disease research with nanomolar BACE1 inhibition and reliable blood-brain barrier penetration, supporting synaptic-sparing amyloid reduction. This article details translational workflows, protocol optimizations, and actionable troubleshooting grounded in cutting-edge evidence.
PD0325901 and the Future of MEK Inhibition in Translational
2026-07-07
This thought-leadership article explores how PD0325901, a potent MEK inhibitor from APExBIO, transforms translational research by enabling precise interrogation of the RAS/RAF/MEK/ERK pathway. We synthesize mechanistic insights, latest experimental evidence, and strategic guidance for researchers targeting cell cycle regulation, apoptosis, and chromatin accessibility in advanced cancer models. The discussion integrates new findings on nucleosome dynamics and contextualizes protocol best practices, setting a higher bar than standard product literature.
N1-Methyl-Pseudouridine-5'-Triphosphate in RNA Therapeutics
2026-07-06
N1-Methyl-Pseudouridine-5'-Triphosphate transforms in vitro transcription workflows, offering enhanced RNA stability and translational efficiency critical for mRNA vaccines and RNA-based immunotherapies. Its integration addresses immunogenicity and degradation challenges, enabling next-generation therapeutic and research applications.
APOC1 Drives Thyroid Carcinoma: Cyclopamine’s Synergistic Po
2026-07-06
This study identifies Apolipoprotein C1 (APOC1) as a driver of papillary thyroid carcinoma (PTC) progression and immune evasion. It further demonstrates that cyclopamine, a Hedgehog signaling inhibitor, acts synergistically with APOC1 depletion to suppress tumor growth, highlighting a promising therapeutic axis for future cancer research.
Multi-Omics Dissection of ARID1A-Driven Resistance in Melano
2026-07-05
This study applies integrative multi-omics to uncover how ARID1A loss reshapes signaling networks and confers resistance to BRAF/MAPK inhibition in melanoma. Key resistance mechanisms—including sustained MAPK and JNK signaling and immune evasion—are identified, offering new directions for targeted and combination therapies.
7828 records 15/522 page Previous Next First page 上5页 1112131415 下5页 Last page